Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diclofenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 8/20 | 0.86 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.86 |
| ▸ | TTR | P02766 | 3/20 | 0.86 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.86 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.86 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.86 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.86 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.86 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.86 |
| ▸ | ALB | P02768 | 1/20 | 0.86 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.86 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.86 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.86 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.86 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.86 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.86 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.86 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.86 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.86 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diclofenac SCHEMBL15669923 | 0.99 | PTGS2 (0.89) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| Diclofenac SCHEMBL18174201 | 0.94 | PTGS2 (0.86) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| Diclofenac SCHEMBL2216520 | 0.94 | PTGS2 (0.97) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| Diclofenac SCHEMBL4566078 | 0.93 | PTGS2 (0.89) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| Diclofenac SCHEMBL7776173 | 0.93 | PTGS2 (0.89) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| Diclofenac SCHEMBL29354260 | 0.93 | PTGS2 (1.00) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| Diclofenac SCHEMBL2799 | 0.93 | PTGS2 (1.00) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| Diclofenac SCHEMBL996716 | 0.93 | PTGS2 (1.00) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| Diclofenac SCHEMBL27984058 | 0.92 | PTGS2 (0.86) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| Diclofenac SCHEMBL6765357 | 0.92 | PTGS2 (0.91) | PTGS2TTRCXCL8PTGS1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120201994-A | Hydroalcoholic single phase gel compositions for topical delivery of diclofenac | 赫力昂消费者保健有限责任公司 | 2025-06-24 | — | — | CN | claimed |
| CN-118647363-A | Diclofenac preparation | 赫力昂瑞士有限责任公司 | 2024-09-13 | — | — | CN | claimed |
| US-11884779-B2 | Ionically modified silicones, compositions, and medical devices formed therefrom | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2024-01-30 | — | — | US | claimed |
| US-11254789-B2 | Ionically modified silicones, compositions, and medical devices formed therefrom | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2022-02-22 | — | — | US | claimed |
| EP-3583177-B1 | IONICALLY MODIFIED SILICONES, COMPOSITIONS, AND MEDICAL DEVICES FORMED THEREFROM | MOMENTIVE PERFORMANCE MAT INC (US) | 2020-12-23 | — | — | EP | claimed |
| EP-3583176-B1 | IONICALLY MODIFIED SILICONES, COMPOSITIONS, AND MEDICAL DEVICES FORMED THEREFROM | MOMENTIVE PERFORMANCE MAT INC (US) | 2020-12-16 | — | — | EP | claimed |
| US-20200231757-A1 | IONICALLY MODIFIED SILICONES, COMPOSITIONS, AND MEDICAL DEVICES FORMED THEREFROM | MOMENTIVE PERFORMANCE MATERIALS INC. | 2020-07-23 | — | — | US | claimed |
| US-20200223985-A1 | IONICALLY MODIFIED SILICONES, COMPOSITIONS, AND MEDICAL DEVICES FORMED THEREFROM | MOMENTIVE PERFORMANCE MATERIALS INC. | 2020-07-16 | — | — | US | claimed |
| CN-110494519-A | Organosilicon, composition through ion modification and the medical equipment formed by it | MOMENTIVE PERFORMANCE MAT INC | 2019-11-22 | — | — | CN | claimed |
| CN-110431203-A | Organosilicon, composition through ion modification and the medical equipment formed by it | MOMENTIVE PERFORMANCE MAT INC | 2019-11-08 | — | — | CN | claimed |
| CN-100350905-C | Treatment of burns | NOVAR TIS CONSUMER HEALTH S A (CH) | 2007-11-28 | — | — | CN | claimed |
| CN-100340237-C | Transdermal drug delivery system with improved water absorbability and adhesion properties | SAMYANG CORP (KR) | 2007-10-03 | — | — | CN | claimed |
| CN-1705472-A | Transdermal drug delivery system with improved water absorbability and adhesion properties | SAMYANG CORP (KR) | 2005-12-07 | — | — | CN | claimed |
| US-6849645-B2 | Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives | SABINSA CORPORATION (US) | 2005-02-01 | — | — | US | claimed |
| CN-1531430-A | Local used composition containing antifungal agent | ŵ�����˹ɷ�����˾ | 2004-09-22 | — | — | CN | claimed |
| CN-1449282-A | Treatment of burns | NOVAR TIS CONSUMER HEALTH S A (CH) | 2003-10-15 | — | — | CN | claimed |
| US-20020058695-A1 | Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives | SABINSA CORPORATION | 2002-05-16 | — | — | US | claimed |
| EP-1159009-A2 | USE OF NIAOULI ESSENTIAL OIL AS TRANSDERMAL PERMEATION ENHANCER | FARMIGEA S.P.A. (IT) | 2001-12-05 | — | — | EP | claimed |
| CN-1271280-A | Transdermal drug delivery system for anti-inflammatory analgesic agent comprising diclofenac diethylammonium salt and method for producing the same | SAM YANG CO (KR) | 2000-10-25 | — | — | CN | claimed |
| WO-2000053228-A2 | USE OF NIAOULI ESSENTIAL OIL AS TRANSDERMAL PERMEATION ENHANCER | FARMIGEA S.P.A. (IT) | 2000-09-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058695-A1 | Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives | QDPR, SLC19A2, VIP | PTGS2 627/4885PTGS1 761/4885TTR 218/4885 |
| US-11254789-B2 | Ionically modified silicones, compositions, and medical devices formed therefrom | ORMDL3, THEM6, ITK | PTGS2 2567/4885PTGS1 2651/4885TTR 2407/4885 |
| US-11884779-B2 | Ionically modified silicones, compositions, and medical devices formed therefrom | ORMDL3, THEM6, WEE1 | PTGS2 2933/4885PTGS1 3022/4885TTR 2870/4885 |
| US-20200231757-A1 | IONICALLY MODIFIED SILICONES, COMPOSITIONS, AND MEDICAL DEVICES FORMED THEREFROM | ORMDL3, THEM6, WEE1 | PTGS2 2933/4885PTGS1 3022/4885TTR 2870/4885 |
| US-20200223985-A1 | IONICALLY MODIFIED SILICONES, COMPOSITIONS, AND MEDICAL DEVICES FORMED THEREFROM | ORMDL3, THEM6, ITK | PTGS2 2567/4885PTGS1 2651/4885TTR 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.